Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ensifentrine - Verona Pharma

Next Previous
Search
Drug Profile

Ensifentrine - Verona Pharma

Alternative Names: Ohtuvayre; RPL 554

Latest Information Update: 12 Mar 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Vernalis
  • Developer Nuance Pharma; Verona Pharma
  • Class Anti-inflammatories; Antiallergics; Antiasthmatics; Antibronchitics; Antifibrotics; Imines; Isoquinolines; Small molecules; Urea compounds
  • Mechanism of Action Cystic fibrosis transmembrane conductance regulator stimulants; Type 3 cyclic nucleotide phosphodiesterase inhibitors; Type 4 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Chronic obstructive pulmonary disease
  • Phase II Asthma; Bronchiectasis; Cystic fibrosis
  • Phase I Allergic asthma
  • Discontinued Allergic rhinitis; COVID 2019 infections

Most Recent Events

  • 27 Feb 2025 Verona Pharma intends to commence regulatory processes to support potential marketing authorization applications (MAAs) for Ensifentrine in the EU and UK for the treatment of chronic obstructive pulmonary disease (COPD) in 2025
  • 07 Feb 2025 Preregistration for Chronic obstructive pulmonary disease in Macau (Inhalation), prior to February 2025
  • 07 Feb 2025 Registered for Chronic obstructive pulmonary disease in Macau (Inhalation)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top